18F-FDG PET/CT对接受抗CD19 CAR-T治疗的侵袭性B细胞淋巴瘤患者的预后价值
该回顾性研究分析72例侵袭性B细胞淋巴瘤患者接受CAR-T输注前、输注时及输注后1个月的18F-FDG PET/CT代谢参数,评估其对无进展生存(PFS)和总生存(OS)的预测价值。结果显示输注前肿瘤代谢体积动力学参数对PFS的区分能力优于初始肿瘤负荷,而输注后1个月SUVmax是OS的最强预测因子。
要点
- 输注前ΔMTVpre-CAR和ΔTLGpre-CAR对PFS的预测优于输注前代谢参数。
- ΔMTVpre-CAR<300%者中位PFS为6.8个月,≥300%者为2.8个月(P=0.004)。
- 输注后1个月SUVmax cutoff值14是多变量分析中OS的最强预测因子(P<0.0001)。
核心结论
- CAR-T输注前肿瘤代谢体积动力学参数对PFS的预测优于初始肿瘤负荷。
- 输注后1个月SUVmax可有效区分不同预后的OS患者。
研究设计与样本
- 回顾性分析72例接受抗CD19 CAR-T治疗的侵袭性B细胞淋巴瘤患者。
- 分析白细胞分离前、CAR-T输注前及输注后1个月(M1)的18F-FDG PET/CT数据。
- 计算SUVmax、总病灶糖酵解(TLG)、代谢肿瘤体积(MTV)及肿瘤动力学参数。
主要发现
- ΔMTVpre-CAR<300%者中位PFS为6.8个月(95%CI 2.8个月至未达到),≥300%者为2.8个月(95%CI 0.9-3.0个月),P=0.004。
- ΔTLGpre-CAR<420%者中位PFS为6.8个月(95%CI 2.8个月至未达到),≥420%者为2.7个月(95%CI 1.3-3.0个月),P=0.0148。
- M1时SUVmax cutoff值14在多变量分析中最具预测性,优于其他临床生物学变量(P<0.0001)。
关键数值与推荐
- ΔMTVpre-CAR阈值300%用于区分PFS。
- ΔTLGpre-CAR阈值420%用于区分PFS。
- M1时SUVmax cutoff值14用于预测OS。
临床怎么用
- 可利用输注前18F-FDG PET/CT代谢体积动力学参数辅助预测CAR-T治疗后PFS。
- 输注后1个月SUVmax有助于识别OS预后不同的患者群体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OF THE REPORT: We aimed to evaluate the role of 18F-FDG PET/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma. METHODS: 18F-FDG PET/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each 18F-FDG PET/CT performed. The aim was to evaluate the prognostic value of 18F-FDG PET/CT metabolic parameters for predicting progression-free survival (PFS) and overall survival (OS) following CAR T-cell therapy. RESULTS: Regarding PFS, ∆MTVpre-CAR and ∆TLGpre-CAR were found to be more discriminating compared with metabolic parameters at preinfusion. Median PFS in patients with a ∆MTVpre-CAR of less than 300% was 6.8 months (95% confidence interval [CI], 2.8 months to not reached) compared with 2.8 months (95% CI, 0.9-3.0 months) for those with a value of 300% or greater (P = 0.004). Likewise, median PFS in patients with ∆TLGpre-CAR of less than 420% was 6.8 months (95% CI, 2.8 months to not reached) compared with 2.7 months (95% CI, 1.3-3.0 months) for those with a value of 420% or greater (P = 0.0148). Regarding OS, metabolic parameters at M1 were strongly associated with subsequent outcome. SUVmax at M1 with a cutoff value of 14 was the most predictive parameter in multivariate analysis, outweighing other clinicobiological variables (P < 0.0001). CONCLUSIONS: Disease metabolic volume kinetics before infusion of CAR T cells seems to be superior to initial tumor bulk itself for predicting PFS. For OS, SUVmax at M1 might adequately segregate patients with different prognosis.
引用
- Sesques P, Tordo J, Ferrant E, et al. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells. Clin Nucl Med. 2021. PMID: 34115706. doi:10.1097/RLU.0000000000003756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。